Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

Cell Reports(2022)10.1016/j.celrep.2022.110814Source: DataRank Database

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 134 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access134 citations

Download PDF

Cite:

Linked data & code

cellosaurus nct rrid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (27 grants)OA: goldTopics (47)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Rebecca Caeser ORCID,Shweta S. Chavan ORCID,Yingqian A. Zhan ORCID,Andrew Chow ORCID,Parvathy Manoj ORCID

Live enrichment

PubMed:35584676 PMC:PMC9449677

Yasuda Memorial Medical Foundation

Grant: K08 CA-248723

Yasuda Memorial Medical Foundation

Grant: R01 CA197936

Yasuda Memorial Medical Foundation

Grant: U24 CA213274

National Cancer Institute

Grant: R01 CA258784

Stand Up To Cancer

Grant: P30 CA008748

NCI NIH HHS

Grant: R35 CA263816

NCI NIH HHS

Grant: K08 CA248723

National Institutes of Health

Grant: 5R01CA197936-02

Determinants of acquired resistance in small cell lung cancer

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5K08CA248723-03

Assessment of Tim-4+ Pleural Macrophages as Negative Regulators of Anti-Tumor T Cell Immunity in Lung Cancer

National Institutes of Health

Grant: 5U24CA213274-02

Coordinating center for the NCI small cell lung cancer research consortium

Jazz Pharmaceuticals

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R01CA258784-05

Targeting replication stress signaling to overcome immune evasion in small cell lung cancer

Jazz Pharmaceuticals

Marie-Josée and Henry R. Kravis Center for Molecular Oncology

University of Utah

Parker Institute for Cancer Immunotherapy

Dana-Farber Cancer Institute

Entertainment Industry Foundation

Congressionally Directed Medical Research Programs

Memorial Sloan-Kettering Cancer Center

Meso Scale Diagnostics

Cycle for Survival

American Association for Cancer Research

Fiona and Stanley Druckenmiller Center for Lung Cancer Research

Merck

National Institutes of Health

goldLicense: cc-by

publisherhttp://www.cell.com/article/S221112472200585X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S221112472200585X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S221112472200585X?httpAccept=text/plain

repositoryhttps://doaj.org/article/ab09d4c714e64f25a536b12f1cde0a86

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9449677

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Cell Line, TumorAnimalsMiceLung NeoplasmsCell Cycle ProteinsMembrane ProteinsAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsDrug SynergismSTAT1 Transcription FactorProtein-Tyrosine KinasesSmall Cell Lung CarcinomaB7-H1 AntigenImmune Checkpoint InhibitorsSTING Protein

Keywords

InterferonImmunotherapyPD-L1SCLCImmune Checkpoint BlockadeWee1 InhibitionSting PathwayCd8(+) T cellsCp: ImmunologyCp: CancerStat1 PathwayLung NeoplasmsQH301-705.5Membrane ProteinsCell Cycle ProteinsDrug SynergismProtein-Tyrosine KinasesSmall Cell Lung CarcinomaArticleB7-H1 AntigenMiceSTAT1 Transcription FactorSTING ProteinCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsAnimalsBiology (General)Immune Checkpoint InhibitorsProtein Kinase Inhibitors

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.25951818.v1figshare

Additional file 1 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.25951818figshare

Additional file 7 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728375.v1figshare

Additional file 7 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728375figshare

Additional file 8 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728378.v1figshare

Additional file 8 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728378figshare

Additional file 5 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728369.v1figshare

Additional file 6 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728372.v1figshare

Additional file 5 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728369figshare

Additional file 6 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728372figshare

Additional file 2 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.25951948.v1figshare

Additional file 4 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728366figshare

Additional file 3 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728363figshare

Additional file 4 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728366.v1figshare

Additional file 2 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.25951948figshare

Additional file 3 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

10.6084/m9.figshare.26728363.v1figshare

Additional file 5 of Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

10.6084/m9.figshare.26650422figshare

Additional file 4 of Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

10.6084/m9.figshare.26650419figshare

Additional file 6 of Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

10.6084/m9.figshare.26650425.v1figshare

Additional file 4 of Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

10.6084/m9.figshare.26650419.v1figshare

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

FAIR Checklist

Authors (20)

Funding (27 grants)

Open Access

Topics

Linked Datasets (25)

Annotations (Europe PMC)